Exercise: According to current clinical guidelines for multiple sclerosis patients, the progressive resistance training (PRT) protocol will be implemented as follows: a 12-week intervention consisting of three supervised 60-90 minutes sessions per week at 60-80% of one-repetition maximum intensity. All training sessions will be conducted under the direct supervision of a certified physiotherapist to ensure proper technique adherence and safety throughout the intervention period
Study summary
This single-blind, randomized controlled trial will employ a two-arm parallel design (exercise group vs. control group) with a 12-week intervention period. Randomization will be implemented using SPSS 25.0 (IBM Corporation, Armonk, NY, USA) to ensure balanced group allocation. All outcome measures will be assessed at baseline and post-intervention.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Clinically confirmed relapsing-remitting multiple sclerosis (RRMS) diagnosis according to revised McDonald criteria (2017)
* Mild-to-moderate disability (EDSS score 1.0-5.5)
* No corticosteroid treatment within the previous 3 months
Exclusion Criteria:
* Acute MS relapse within 90 days before enrollment
* Regular participation in structured exercise programs (\>3 hours/week)
* Comorbid conditions that may limit exercise participation, including significant orthopedic impairments, unstable cardiopulmonary conditions, and other systemic disorders affecting physical activity
* Standard MRI contraindications (metallic implants, claustrophobia, etc.)
* Concurrent neurological disorders (other than MS)
* Initiation or modification of disease-modifying therapy within 6 months
* Severe spasticity (Modified Ashworth Scale ≥3 in any major muscle group)
Primary outcome measure(s)
MRI Acquisition and Volumetric Analysis — 12 Weeks Volumetric brain analysis will be conducted using VolBrain, an open-access automated segmentation platform for brain MRI.
Serum Glial Fibrillary Acidic Protein measurement — 12 Weeks All patients will be asked to provide blood samples in the morning following their overnight (12 h) fast before and after the study. The unit ng/ml will be used for serum Glial Fibrillary Acidic Protein.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
